SION

Sionna Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality0/10
  • Growth↑ 6/10
  • Momentum↑ 8/10
Sionna Therapeutics sales and earnings growth
SION Growth
Good
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 71.05%
  • FCF Y/Y↓ -26.91%
Sionna Therapeutics gross and profit margin trends
SION Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC↓ -27.40%
Sionna Therapeutics net debt vs free cash flow
SION Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Sionna Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗